Shilanski & Associates’s Genmab GMAB Stock Holding History

Shilanski & Associates’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-5,120	Closed	-$217K	–	114
2022 Q4	$217K	Buy	+5,120	New	+$211K	0.09%	98

Other funds holding GMAB

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Shilanski & Associates's GMAB Position: Q1 2023 in Review

Shilanski & Associates sold out of Genmab (GMAB) in Q1 2023, closing a stake of 5,120 shares — an estimated $217K sold.

Shilanski & Associates first reported a position in GMAB in Q4 2022 and held it in 1 quarter. The position peaked at $217K in Q4 2022. 216 funds tracked by Wall St. Rank hold GMAB as of Q1 2023.

Shilanski & Associates reported no remaining Genmab position as of Q1 2023 after selling out during the quarter.
Shilanski & Associates sold 5,120 Genmab shares in Q1 2023, an estimated $217K.
Shilanski & Associates first reported a position in Genmab in Q4 2022 and held it in 1 quarter.
Shilanski & Associates's Genmab position peaked at $217K in Q4 2022.
216 funds tracked by Wall St. Rank held Genmab as of Q1 2023.

Based on Shilanski & Associates's 13F filing for Q1 2023, filed 12 May 2023.